INTRAVENOUS CLARITHROMYCIN: A VALUABLE IMMUNOMODULATOR FOR SEVERE INFECTIONS
There are many studies suggesting that intake of a macrolide in the treatment regimen is linked with improved outcomes for patients with community-acquired pneumonia. However this was never proved through one randomized clinical study (RCT). We reviewed all pre-clinical and clinical development from...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Association of medical doctors Sanamed Novi Pazar
2014-04-01
|
| Series: | Sanamed |
| Subjects: | |
| Online Access: | http://www.sanamed.rs/sanamed_pdf/sanamed_9_1/Konstantinos_Leventogian.pdf |
| _version_ | 1797285513330163712 |
|---|---|
| author | Leventogiannis Konstantinos Giamarellos-Bourboulis J. Evangelos |
| author_facet | Leventogiannis Konstantinos Giamarellos-Bourboulis J. Evangelos |
| author_sort | Leventogiannis Konstantinos |
| collection | DOAJ |
| description | There are many studies suggesting that intake of a macrolide in the treatment regimen is linked with improved outcomes for patients with community-acquired pneumonia. However this was never proved through one randomized clinical study (RCT). We reviewed all pre-clinical and clinical development from 2003 to 2014 for intravenous clarithromycin as adjunctive treatment of severe infections. This process
ended with the conduct of two RCTs; the first in 200 patients with ventilator-associated pneumonia; and the second in 600 patients with proven or suspected Gram-negative infections of non-pulmonary origin. The two RCTs has similar findings; significant decrease of mortality of patients with septic shock and multiple organ dysfunctions; and shorter resolution of severe infections. The second RCT also showed significant
savings for survivors. These data support the use of intravenous clarithromycin as adjunctive treatment of severe infections. |
| first_indexed | 2024-03-07T18:04:18Z |
| format | Article |
| id | doaj.art-2a422ec9341441e393316890487e2ae4 |
| institution | Directory Open Access Journal |
| issn | 1452-662X 2217-8171 |
| language | English |
| last_indexed | 2024-03-07T18:04:18Z |
| publishDate | 2014-04-01 |
| publisher | Association of medical doctors Sanamed Novi Pazar |
| record_format | Article |
| series | Sanamed |
| spelling | doaj.art-2a422ec9341441e393316890487e2ae42024-03-02T09:45:16ZengAssociation of medical doctors Sanamed Novi PazarSanamed1452-662X2217-81712014-04-01918387INTRAVENOUS CLARITHROMYCIN: A VALUABLE IMMUNOMODULATOR FOR SEVERE INFECTIONSLeventogiannis Konstantinos0Giamarellos-Bourboulis J. Evangelos14th Department of Internal Medicine, University of Athens, Medical School, Greece4th Department of Internal Medicine, University of Athens, Medical School, GreeceThere are many studies suggesting that intake of a macrolide in the treatment regimen is linked with improved outcomes for patients with community-acquired pneumonia. However this was never proved through one randomized clinical study (RCT). We reviewed all pre-clinical and clinical development from 2003 to 2014 for intravenous clarithromycin as adjunctive treatment of severe infections. This process ended with the conduct of two RCTs; the first in 200 patients with ventilator-associated pneumonia; and the second in 600 patients with proven or suspected Gram-negative infections of non-pulmonary origin. The two RCTs has similar findings; significant decrease of mortality of patients with septic shock and multiple organ dysfunctions; and shorter resolution of severe infections. The second RCT also showed significant savings for survivors. These data support the use of intravenous clarithromycin as adjunctive treatment of severe infections.http://www.sanamed.rs/sanamed_pdf/sanamed_9_1/Konstantinos_Leventogian.pdfclarithromycincytokinesinflammationsepsis |
| spellingShingle | Leventogiannis Konstantinos Giamarellos-Bourboulis J. Evangelos INTRAVENOUS CLARITHROMYCIN: A VALUABLE IMMUNOMODULATOR FOR SEVERE INFECTIONS Sanamed clarithromycin cytokines inflammation sepsis |
| title | INTRAVENOUS CLARITHROMYCIN: A VALUABLE IMMUNOMODULATOR FOR SEVERE INFECTIONS |
| title_full | INTRAVENOUS CLARITHROMYCIN: A VALUABLE IMMUNOMODULATOR FOR SEVERE INFECTIONS |
| title_fullStr | INTRAVENOUS CLARITHROMYCIN: A VALUABLE IMMUNOMODULATOR FOR SEVERE INFECTIONS |
| title_full_unstemmed | INTRAVENOUS CLARITHROMYCIN: A VALUABLE IMMUNOMODULATOR FOR SEVERE INFECTIONS |
| title_short | INTRAVENOUS CLARITHROMYCIN: A VALUABLE IMMUNOMODULATOR FOR SEVERE INFECTIONS |
| title_sort | intravenous clarithromycin a valuable immunomodulator for severe infections |
| topic | clarithromycin cytokines inflammation sepsis |
| url | http://www.sanamed.rs/sanamed_pdf/sanamed_9_1/Konstantinos_Leventogian.pdf |
| work_keys_str_mv | AT leventogianniskonstantinos intravenousclarithromycinavaluableimmunomodulatorforsevereinfections AT giamarellosbourboulisjevangelos intravenousclarithromycinavaluableimmunomodulatorforsevereinfections |